---
title: Improve speech loudness and clarity
nct_id: NCT06416553
phase: NA
status: RECRUITING
sponsor: Masaryk University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06416553"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06416553"
last_fetched: "2026-05-10T14:06:19.516Z"
source: "Parkinson's Pathways (curated)"
---
# Improve speech loudness and clarity

**Goal (in five words):** Improve speech loudness and clarity

**Official Title:** Home-based Non-invasive Brain Stimulation in Combination With Lee Silverman Voice Treatment on Hypokinetic Dysarthria in Parkinson's Disease

**Trial ID:** [NCT06416553](https://clinicaltrials.gov/study/NCT06416553)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Masaryk University
- **Target Enrollment:** 40 participants
- **Start Date:** 2023-01-10
- **Completion Date:** 2025-11-15
- **Conditions:** Parkinson Disease
- **Interventions:** Home-based transcranial direct current stimulation- real tDCS, Home-based transcranial direct current stimulation- sham tDCS, Lee-Silverman voice treatment
- **Intervention Types:** DEVICE, BEHAVIORAL

## Summary For Families

The goal is to help with hypokinetic dysarthria, the soft, monotone or unclear speech many people with Parkinson's develop. The approach pairs home-based transcranial direct current stimulation, which uses a weak electrical current to gently boost activity in speech-related brain areas, with Lee Silverman Voice Treatment, an intensive program that trains louder, clearer speech, and participants get either real or sham tDCS while doing the voice therapy to see if stimulation adds benefit. They are enrolling adults 50 to 85 with clinically established Parkinson's who can cooperate, excluding people with major psychiatric disorders or hallucinations, dementia, epilepsy, or MRI-incompatible metal in the body.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* patients with clinically established PD (Postuma et al. 2016)

Exclusion Criteria:

* psychiatric disorders, including major depression, hallucinations
* any MRI-incompatible metal in the body
* epilepsy
* lack of cooperation
* presence of dementia
```

## Locations (1)

- Central European Institute of Technology, Brno, Czechia _(49.1952, 16.6080)_
  - Lubos Brabenec — (CONTACT) — +420731076102 — lubos.brabenec@ceitec.muni.cz

## Central Contacts

- Lubos Brabenec — (CONTACT) — +420731076102 — lubos.brabenec@ceitec.muni.cz

---

*Canonical: https://parkinsonspathways.com/trial/NCT06416553*  
*HTML version: https://parkinsonspathways.com/trial/NCT06416553*  
*Source data: https://clinicaltrials.gov/study/NCT06416553*